Global Immune Repertoire Sequencing Market to Surpass US$ 185 Million by 2026 – Coherent Market Insights

SEATTLE–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24CMI&src=ctag” target=”_blank”gt;$CMIlt;/agt; lt;a href=”https://twitter.com/hashtag/AutoimmuneDiseases?src=hash” target=”_blank”gt;#AutoimmuneDiseaseslt;/agt;–According to Coherent Market Insights, the global immune repertoire
sequencing market was valued at US$ 114.3 million in 2017, and is
projected to exhibit a CAGR of 5.6% over the forecast period (2018–2026).

Key Trends and Analysis of the Immune Repertoire Sequencing Market:

Discovery of various innovative disease-related biomarkers using
next-gen immune repertoire sequencing data is expected to fuel growth of
the immune repertoire sequencing market, globally. For instance,
Haystack Heuristic biomarker for autoimmune disease is an algorithm
customized to computationally extract disease-associated motifs from
next-generation-sequenced repertoires for contrasting disease and
healthy subject.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1517

Growing healthcare infrastructure in various emerging economies such as
Japan and China are expected to fuel growth of the global immune
repertoire sequencing market. Developments by China and Japan for the
integration of new technologies in biomedical research, including
technological advancements in genome sequencing, are expected to boost
growth of the immune repertoire sequencing market.

High throughput immune repertoire sequencing is promising new
statistical diagnostic tools enabling large-scale characterization of
functional antibody repertoires. These repertoires are new methods for
understanding protective and pathogenic immune responses of medicine and
biology of vaccine development to target specific cancer cells and
development of immune therapy against cancer progression. Therefore,
high throughput sequencing of both immunoglobulin and TCR sequences
create numerous opportunities for growth of the immune repertoire
sequencing market.

Technological advancements such as high-throughput screening, new
software-based platforms, and high adoption rate of immune repertoire
sequencing with new technology are factors expected to drive growth of
the global market. For instance, Illumina, Inc. introduced the
NovaSeq Series, a new and scalable sequencing architecture, designed to
allow researchers to access next-generation sequencing technology and
conduct large-scale genomics projects with greater sample volumes.

Key players are launching innovative products in the market, in order to
increase its market share. Such innovative products are addressing
various clinical needs of patients, which is expected to create
conducive environment for growth of the immune repertoire sequencing
market. For instance, in 2016, ArcherDX, Inc., a U.S.-based company,
expanded its product portfolio with the launch of Archer Immunoverse
immune repertoire sequencing assays at the American Society of
Hematology (ASH). In 2017, ArcherDX, Inc. launched Archer Immunoverse B
Cell Receptor (BCR) assays to characterize the human B cell repertoire.

To know the latest trends and insights prevalent in this market,
click the link below:

https://www.coherentmarketinsights.com/market-insight/immune-repertoire-sequencing-market-1517

Key Market Takeaways:

  • The global immune repertoire sequencing market is expected to exhibit
    CAGR of 5.6% during the forecast period (2018–2026). Major players in
    the market are involved in strategic partnership and collaborations,
    in order to develop immune repertoire sequencing services to
    customers. For instance, in March 2018, ArcherDX Inc. and Ambry
    Genetics entered into strategic partnership to provide immune
    repertoire sequencing services to biopharmaceutical customers. As per
    the partnership agreement, Ambry Genetics will use ArcherDX’s
    Immunoverse and VariantPlex next-generation sequencing assays for
    immune repertoire sequencing.
  • Key players operating in the global immune repertoire sequencing
    market include Thermo Fisher Scientific, Inc., Illumina Inc.,
    ArcherDX, Inc., Roche Holding AG, Pacific Biosciences, CD Genomics,
    Atreca, Inc., Adaptive Biotechnologies, Oxford Nanopore Technologies,
    Ltd., Qiagen N.V., Agilent Technologies, Inc., and Takara Bio, Inc.

Inquire
before Buying

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting
firm offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.

Contacts

Mr. Shah
Coherent Market Insights
1001 4th Ave.
#3200
Seattle,
WA 98154
Tel: +1-206-701-6702
Email:[email protected]

error: Content is protected !!